Skip to main content
. 2011 Dec 9;33(2):413–419. doi: 10.1093/carcin/bgr291

Fig. 4.

Fig. 4.

(A) Cell free biochemical-based kinase assay was evaluated (α-mangostin 1 and 10 μM) against JNK 1/2/3, CylinA1/CDK2, cyclinA2/CDK2, CyclinD1/CDK4 and CyclinD3/CDK6. Statistical analysis was performed using VassarStats software by one way analysis of variance and statistical significance was performed by the Tukey test with *P < 0.01. (B) Cell free biochemical kinase assay established the IC50 of α-mangostin against CyclinD1/CDK4. Data points are represented by the average of three values with standard deviation. As a positive control staurosporine, a potent microbial-derived general kinase inhibitor was used (data not shown). Statistical analysis was performed using VassarStats software by one way analysis of variance and statistical significance was performed by the Tukey test with *P < 0.01.‘a’ versus control, ‘b’ versus 2.5 μM, ‘c’ versus 5 μM, ‘d’ versus 7.5 μM, ‘e’ versus 10 μM.